Drug repositioning has gained strategic value as a reaction to high attrition rates of new
drugs as they pass through the clinical development process. The 5-HT2C receptor agonist …

Changes in dopaminergic and noradrenergic transmission are considered to be the
underlying cause of attention deficit and hyperactivity disorder (ADHD). Atomoxetine (ATX) …

Methylphenidate (MPH) is used clinically to treat attention-deficit/hyperactivity disorder
(ADHD) and off-label as a performance-enhancing agent in healthy individuals. MPH …

Agonistic profiles of AMPA receptor (AMPA-R) potentiators may be associated with seizure
risk and bell-shaped dose-response effects. Here, we report the pharmacological …

Abstract Background The rodent Continuous Performance Test (rCPT) is an analogue of
human CPTs where mice have to discriminate between target and non-target stimuli. The …

Rationale A novel rodent continuous performance test (CPT) was developed as one of the
goals of the NEWMEDS (Novel Methods leading to New Medications in Depression and …

Background Noradrenaline is a major neuromodulator in the central nervous system, and it
is involved in the pathophysiology of diverse neuropsychiatric diseases. Previous …

Background: Few studies have investigated the effects of conventional attention deficit-
hyperactivity disorder (ADHD) medication in the mouse 5-choice serial reaction time task (5 …

Background Mice with functional ablation of the neurokinin-1 receptor gene (NK1R−/−)
display behavioural abnormalities which resemble the hyperactivity, inattention and …

Background Noradrenaline has an important role as a neuromodulator of the central
nervous system. Noradrenergic enhancement was recently shown to enhance glutamate …